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ABSTRACT
Cancer is a devastating disease which affects millions. For this reason, many scientists are
working to develop drugs that can specifically target cancer cells within the body. Preclinical
trials are an important phase in the drug development process, as they allow scientists to
determine whether or not a drug candidate may be viable for human use. Targeted therapies can
be achieved by using monoclonal antibodies as well as small molecule drugs. In this study we
compared the effects of two control monoclonal antibody drugs, “mAb1” and “mAb2,” with
one small molecule drug, “Drug S,” on the MDAMB231 human breast cancer cell line in a
xenograft SCID mouse model. All treatment groups containing Drug S exhibited the same trends
as the negative control, mAb1, suggesting Drug S is an ineffective tumorreducing treatment.
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Chapter 1: Introduction
1.1 Background and Motivation
Cancer continues to be one of the leading causes of death, accounting for one in seven deaths
throughout the world, and one in every four deaths in the United States. There are many
contributing factors which may cause cancer, including external factors such as smoking and
diet, and internal factors such as genetics. Cancer occurs when cells begin to grow too quickly.
This rapid proliferation soon begins crowding out and destroying the body’s healthy cells. Most
cancers form lumps or growths called tumors. These lumps can be characterized as being benign,
noncancerous, or else malignant, cancerous. Treatment for cancer aims to reduce or eliminate
1
these tumors.

Our study is specific to breast cancer, which ranks second among cancercausing deaths in
women, with one in eight women being diagnosed with breast cancer in her lifetime. Treatment
of breast cancer usually involves either breastconserving surgery by surgically removing tumors
and the surrounding tissue or mastectomy (surgical removal of the breast). Treatment can also
include radiation, hormone therapy and chemotherapy. Some targeted therapies are available, but
pharmaceutical companies are constantly discovering new and improved therapies that
1
specifically target cancer cells.

1.2 Project Overview
We spent a year working in the labs of Bayside BioSciences, a pharmaceutical contracting
company. Their primary projects involve preclinical testing, both 
in vitro
and 
in vivo
, for various
pharmaceutical products. Over the course of this project we analyzed the effects of potential
cancer therapies in the preclinical stage of the drug development process. Our work began with
in vitro
experiments to grow the MDAMB231 breast cancer cell line. After proliferating the
MDAMB231 cells we injected them into breast tissue of mouse models to induce tumor growth
in vivo
. Following tumor growth, we injected the test compounds to determine their efficacy and
safety within a mouse model. We evaluated the results in the context of control tests and drug

1

cocktails obtained from these experiments to ascertain the viability of moving the compound
further through preclinical testing.

1.3 Problem Statement
Current cancer treatments do not have specific targeting abilities. Pharmaceutical companies are
creating drug candidates for this purpose in order to develop a more effective cancer treatment.
For our senior design project, we conducted a study to determine the efficacy of three drug
candidates in combating the growth of human breast cancer cells in immunodeficient mice.
1.4 Significance
Preclinical testing is an important aspect of progressing a drug from the developmental stage to
market. Before a drug can be administered in clinical trials it must go through a series of
preclinical trials to ensure the safety of clinical trial patients. In the event that these drugs are
efficacious they could serve as a novel alternative to current cancer therapies. A combination of
these drugs could provide a highly specific targeted therapy to eliminate cancer cells while
conserving noncancer cells. If the tests we conduct produce favorable results, the tested drugs
may continue into higher level preclinical trials.

1.5 Literature Review
MDAMB231 Cell Line
The MDAMB231 breast cancer cell line has been used in numerous cancer studies to test the
efficacy of cancer treatments. This cell line is often used to model metastasis, the migration of
cancer cells to other parts of the body. Through gene regulation, the MDAMB231 cell source
also allows for a variety of efficacious breast cancer tumor models. Study procedures utilizing
MDAMB231 cells can more accurately represent human breast cancer conditions when
injected into the mammary fat pads of immunodeficient mice. The use of an orthotopic injection
site allows studies to successfully model the growth and spread of MDAMB231 cancer cells
because the environmental conditions and hormone availability is representative of that in a
human model. The use of immunodeficient mice is advantageous as it removes the host

2

specimen’s ability to attack the foreign cancer cells. This allows the MDAMB231 cells to grow
2
at a faster rate and more quickly model the effects of cancer therapies.

Antibody Drugs
Antibodies are proteins that help the immune system identify foreign substances. Monoclonal
antibodies are manufactured using a type of cell called a hybridoma, which multiples, producing
a continuous supply of the antibody. Monoclonal antibodybased treatment of cancer is one of
3
the most successful therapeutic strategies for tumor reduction.
These antibodies are used to

target specific antigens, or protein targets on the surface of cancer cells. The FDA has approved
several monoclonal antibody products. 
Trastuzumab is a humanized antibody that has been
proven effective in combination with chemotherapy for patients with the human epidermal
4
growth factor receptor 2/
neu
positive breast cancer.
Additionally, hundreds of monoclonal

antibodies are currently at different stages of clinical trials. In one study, the expression of
ganglioside GD2 was discovered on breast cancer stem cells. This is an ideal potential target for
antitumor immunotherapy due to its high expression on cancer cells and restricted expression on
normal tissue. In this study four antiGD2 antibodies have been developed and tested in the
5
clinic: 3F8, hu3F8, ch14.18 and hu14.18.
Future studies of tumor cells and the molecular

pathways which are involved in the development of human cancers could help in identification
of more cell surface antigens. This could provide additional therapeutic targets for more effective
monoclonal antibody based products.

Small Molecule Drugs
Small molecule drugs often work as inhibitors of receptor tyrosine kinases (RTK’s). During
tumor growth and formation these RTK’s are often deregulated, allowing cancer cells to grow
abnormally quickly. The small molecule drugs, by acting as ATP mimetics, are able to inactivate
6
the proteins in the kinases, which in turn slows the growth.
Through targeting kinase activity,

studies have shown it is often the case that normal cells are able to survive inhibition of the
7
kinase activity whereas tumor cells cannot, providing a selective targeting mechanism.
One

benefit through using small molecule drugs is they are capable of passing through plasma

3

6
membranes.
This allows them to interact within the cytoplasm through both receptors and

intracellular signaling molecules. Small molecule drugs offer a specificity in targeting cancer
7
cells without harming normal cells that provides many opportunities for potential cures.

1.6 Team Management
We worked with Bayside BioSciences, a pharmaceutical contracting company, under the
instruction of Dr. Ying Liu and Dr. Frank Xie. Our professional partnership with Bayside
BioSciences required that we sign a nondisclosure agreement to protect the company’s
intellectual property. In addition to this partnership, we were under the advisement of Dr.
Zhiwen Zhang of Santa Clara University’s Bioengineering Department.

1.7 Budget
We received a generous grant of $2,500 from Ms. Jayshree Ullal’s SITA Foundation Dean’s
Fund. These funds went towards the purchase of SCID mice, cell culturing media, and other
supplies. All other expenses were covered by Bayside BioSciences.

1.8 Timeline

Figure 1.1: Project timeline

4

During the fall quarter of 2015 we were educated in good laboratory practices through laboratory
and biosafety training at Bayside BioSciences. We observed and aided in the data collection of
numerous tumor reducing efficacy studies. During this time we also practiced mammalian cell
culturing technique. In the winter quarter of 2016 we conducted our study. This included dosing
and collecting weight and tumor measurements. During the spring quarter of 2016 we finished
analyzing our data and prepared for our senior design presentation and thesis.

5

Chapter 2: Constraints

2.1 Current Methods
There are two categories of treatment methods for breast cancer. Local therapies, such as surgery
and radiation therapy, target the site of tumor growth. Systemic therapies, including
chemotherapy, hormone therapy, and targeted therapy, are not specifically applied, and therefore
may affect more than just the cancer cell target. Surgical removal of breast tumors can be as
simple as a partial mastectomy, when the tumor and tissue around it is removed, and as extreme
as a total mastectomy, when all of the breast tissue and sometimes the lymph nodes are
completely removed. Surgical removal of the breasts is an invasive procedure which can be
difficult for women to decide to do. Additionally, while surgery may physically remove all
cancerous tissue, there may be some remaining cancer cells requiring continuing radiation or
8
hormone treatments.
Chemotherapy is a commonly used therapy involving small molecule

drugs administered intravenously or orally, and subsequently circulates throughout the body.
This method targets cancer cells by inhibiting specific steps in the process of cell division,
causing apoptosis, or cell death. Common negative side effects of chemotherapy, including loss
of appetite and low blood count, can leave the patient feeling sick and weak during treatment.
Since chemotherapy is a systemic therapy, it also risks causing permanent damage to
9
noncancerous cells and can therefore risks organ failure.
Our study uses a targeted therapy

involving a combination of a small molecule drug and a monoclonal antibody. The small
molecule drug functions by releasing molecules which target signaling pathways within cancer
cells to cease cell growth and/or initiate apoptosis. Similarly, monoclonal antibodies are signal
proteins which can bind to specific receptor proteins on the outside of cancer cells, prompting the
cell to take in the signal protein. Once the signal protein is inside the cell, the drug attached to it
will be released and will then kill the cell. This combination of targeted treatments allows for a
10
more specific response and results in fewer mild side effects than chemotherapy drugs alone.

2.2 Engineering Standards and Realistic Constraints
Ethics

6

Due to the fact that our project was done in the preclinical phase of drug development, our
testing was done using 
in vivo
models. Our models, therefore, had to be constructed using live
mice, which may raise some ethical concerns. In order to address these concerns, we were
educated through both the Institutional Animal Care and Use Committee (IACUC) as well as
Good Laboratory Practice (GLP). The IACUC sets guidelines that outline rules and regulations
for animal testing and biosafety. GLP training ensures ethical procedures are taken as well as the
protects the uniformity, consistency, and reproducibility of results. Together, the IACUC and
GLP training allowed us to successfully complete our project while maintaining a paramount
level of ethical practice. In addition to the training we underwent, the laboratory we worked in
went through periodic veterinary checkups and inspections to confirm the animals were being
treated ethically through proper housing, diet, and care.

Another ethical consideration we had to take involved the confidentiality of the study. Since
Bayside Biosciences is a contracting company, they work with third party clients. Due to this
fact, we had to maintain the anonymity and confidentiality of the client’s classified information.
In order to protect this classified information, we could not disclose the identity of the
compounds used in the study.

Health and Safety
We also had to take into consideration the health concerns for both the consumers of the eventual
product as well as the researchers conducting the study. In terms of the consumer, we had to
make sure our research on the drug was precise and accurate to protect their well being. In order
to guarantee their safety, we aimed to provide a factually accurate study, look at the side effects
of the drugs being tested, and create usage warnings as they pertain to pregnancy, age, other
illnesses, and concurrent medications the consumer might be taking. Through providing the
consumer with this knowledge, they can use the drug as intended. The drug we tested would
have to go through more testing before it reached the consumer. Our study was in the preclinical
phase so it is only tested for safety in animals in this stage, following this it would be tested in
humans and then available to the consumer.

7

As for the researchers, we determined the biggest threat to our health and safety during this
project was through the handling of the animals and the sharp objects. The mice we were
working with could be unpredictable and move quickly while we were working with them. This
brought the concern of using sharp objects, like needles and scalpels, near them. The mice could
also bite us if not handled properly. To minimize this safety concern we went through biosafety
training which taught us the safest methods for handling the mice and sharp objects.

Economic
The economic aspect was a significant concern for our project. In order to create a successful
drug, the drug must be cost efficient and accessible to the general public. To do this a balance
must be found in which the drug is affordable, yet at the same time capable of bringing the
pharmaceutical company profit. While it may be legal to inflate the price of a potentially life
11
saving drug, it is not ethical.
From this we realized there is also a distinction to be made

between what is legal and what is ethical.

Manufacturability
The process behind developing new medicines is complicated, expensive, and time consuming
(Figure 2.1). On average, it takes at least 10 years for a new medicine to complete the journey
12
from initial discovery to the marketplace.
Additionally, it costs approximately 2.6 billion
12
dollars to develop a drug that gains market approval.
Once a drug has been discovered, it is sent

through preclinical trials to test its safety on animal models. If the preclinical trial is successful,
the drug candidate may move on to clinical trials, where the drug is assessed further for safety
and efficacy in humans. After clinical studies, the FDA will review the drug and approve it if
applicable. After FDA approval for market, the company continues to monitor the drug for
12
unexpected side effects and additional data.

8

Figure 2.1: Drug development process
Source: 
Pharmaceutical Research and Manufacturers of America

The processes for which monoclonal antibody drugs and small molecule drugs go through are
similar, however they differ in their difficulty of manufacturing. Currently, mAb’s are more
difficult to design and produce due to their larger size and complexity. Furthermore, with mAb’s,
they require an antibody generation step which increases the cost significantly. The cost to
manufacture a mAb is also much higher due to their high specificity for targeted therapies.

Social
On a social level, we had to consider the possibility that while it is legal to test on animals, it
may not be ethical from some perspectives. We also had to keep in mind the possibility for abuse
or misuse of the potential drug. As preclinical drug testers, we can only go so far to ensure the
consumer is assuming ethical responsibility for their welfare. Because side effects differ among
patients, any drug should be taken under physician supervision. However, once out of a
physician’s care, it is the responsibility of the patient to follow the dosing instructions. This is
where the possibility of an overdose arises. Also, a patient may become frustrated with the length

9

of time it takes to cure their disease, so they might attempt increasing their dosage with the hope
it would cure them more quickly.

10

Chapter 3: Design Description
3.1 Format of Study
Table 3.1: Active compounds corresponding to group number

This study includes 8 groups, each containing a different combination of three different drugs
(Table 3.1). Each treatment arm had between five and six mice, for a total of 42 mice in the
study. The first group was a control, containing only the vehicles with no treatment, which acted
as a baseline to which we could compare other groups and eliminate results that may be due to
the vehicle rather than the drug itself. The rest of the groups were created to provide every
combination possible of the three drugs, including each drug on its own and a cocktail of all
three drugs together. By looking at these different drug combinations, the goal is to determine a
which will provide the highest specificity to target the cancer cells. This is especially important
because while we are injecting one type of cancer cell in our 
in vivo
mouse model, human tumors
tend to have much greater variation in cancer cell type, so it is difficult to target them all. It is
therefore important to look at these drugs in combination so we can find a treatment that will
provide the optimum benefit.

3.2 Drug Types
Vehicles
For each drug, we had a corresponding vehicle used in place of the active drug if it was not being
administered to the treatment group. A vehicle is a chemically inactive substance or structure
used as a medium to deliver a drug. An ideal drug delivery vehicle should be nontoxic,
13
biocompatible, nonimmunogenic and biodegradable.

11

Monoclonal Antibody
The first drug type we used were monoclonal antibodies (mAb), which acted as our positive and
negative controls for the study. Therapeutic antibodies have recently become one of the most
successful and important strategies in treating cancer patients. An antibody is a protein with
specialized binding regions which are able to target specific receptors, antigens, on cancer cell
14
surfaces, inhibiting the cell by one of three mechanisms (Figure 3.1).

Figure 3.1: Functions of therapeutic mAb drugs
Source: Loureiro et al.

The first way mAbs can inhibit the tumor cell is that it can initiate the release of enzymes such as
caspases, which causes apoptosis, or cell death. The antibody can also bind with the antigen to
block a different protein, or ligand, from binding to the cell. This prevents an internal signaling
cascade, thereby hindering cell processes important to cell replication. Lastly, the antibody may
be carrying a drug compound to the binding site, releasing it into the cancer cell and allowing it
15
to take effect.

Pharmaceutical companies can create these drugs by first identifying surface proteins specific to
the cancer cell, and then by creating a monoclonal antibody which is able to target that protein.
However, mAbs are very large (~150,000 daltons) (Figure 3.2), and this causes problems with
orally administration because the antibodies cannot pass through the epithelial membrane of the
12

14
digestive tract to get into the circulatory system.
Instead, mAb drugs must be administered via

intravenous injection of intraperitoneal injection. For our study, intraperitoneal injection was
utilized because it is much easier to perform on mice and has a similar effect to intravenous
injection.

Small Molecule
The second drug we used in our design was a small molecule drug, which was the experimental
drug for the preclinical study. Whereas monoclonal antibodies are very large, small molecules
16
are, as their name suggests, much smaller in size (~10 daltons)(Figure 3.2).
The benefit of using

small molecule drugs is that, due to their size, they have high tissue permeability and are
therefore capable of passing through the epithelial membrane in the digestive tract to target other
17
cells in the body.
Because of this, small molecule drugs may be dosed orally, which is much

more convenient for the consumer.

Figure 3.2: Size comparison between small molecule and mAb drugs
Source: Amgen

Rather than targeting receptors on the outside of the cell, these drugs penetrate cancer cell
membranes and bind to proteins inside the cell, altering or inhibiting internal cell pathways, and

13

consequently damaging the cell. Unfortunately, since small molecules are able to permeate many
17
different membranes, they are less specific in the cells that they target relative to antibodies.

The way a pharmaceutical company determines a small molecule drug to use in a study is very
different from a monoclonal antibody. The typical method of choosing a small molecule drug to
test is by running preliminary 
in vitro
tests on thousands of different small molecules from a
library of identified compounds. Then these choices are narrowed down to a select few which
17
show potential efficacy for a trial.

14

Chapter 4: Materials and Methods
4.1 Research Model
For our study, we first created a xenograft cancer model. Xenograft refers to the transplantation
of cells or tissues from one species to another. In our case, this was demonstrated by the
culturing of human breast cancer cells 
in vitro
and the implantation of those cells in mice, where
they were then given different drugs to determine their efficacy on reducing tumor size (Figure
4.1). This process is a common research technique for variations of preclinical oncology
18
research.

Figure 4.1: Drug testing in xenograft models
Source: Roper

For our research, the type of mice we used were severe combined immunodeficient (SCID) mice.
Specifically, CB17 SCID mice, which have a compromised immune system due to impaired or
absent T and B lymphocytes. Lymphocytes are subtypes of white blood cells made in the bone
marrow that account for a critical part of the immune system. T cells are involved in
cellmediated immunity, and B cells are responsible for humoral immunity by creating
19
antibodies.
When T and B lymphocytes are absent or impaired, this prevents the mice’s

immune system from rejecting the foreign xenograft cells, allowing them to grow uninhibitedly
within the mice.

Severe combined immunodeficient mice are very sensitive to infection by a wide range of
normal pathogens, opportunistic pathogens and commensal organisms. This means that the mice
15

had be housed and maintained in a separate room from the other animals in the lab to create a
maximum barrier for infection. Food, water, bedding, cages and anything else that came into
contact with the mice were irradiated, or sterilized, beforehand. Every time the cages were
changed or the mice were handled, it was all done in a sterilized laminar flow hood. Careful
20
handling and attention to detail was essential to housing SCID mice.

4.2 MDAMB231 Cell Line
The xenograft cells we used came from the MDAMB231 cell line originating from the breast
tissue of a 51 year old female. This cell line was derived from a metastatic site which means that
21
this cell line is often used in the study of metastatic cancer.

Figure 4.2: Cancer cells injected into the mammary gland
Source: Russell

Prior to implantation, the cells were grown in culture and were passaged several times. Cell
passaging, or splitting, is a technique that enabled us to keep the cells alive and growing under
cultured conditions until the mice were ready for implantation. At that point, the cells were
isolated from the cell culture and resuspended in Matrigel. Matrigel is a liquid matrix containing
support proteins and growth factors which help the foreign breast cancer cells attach and
22
differentiate within the mice.

16

For this study, mice were given an anesthetic and were then injected with a specific volume of
the cell solution containing approximately 2 million cells per injection. Most tumor xenografts
are injected subcutaneously on the backs of the mice. However, to more accurately model the
hormones and other factors that play a role in breast cancer development in humans, our
xenograft injections were made on the underside of the mice, in the mammary fat pads between
23
the skin and muscle (Figure 4.2).
The mammary fat pad model is currently the preferred

location of transplanting human breast cancer cells. Using this model, the tumor cells can be
tracked as they move through the blood and lymphatic vessels within the mammary gland and
23
metastasize, or spread, to other organs.

4.3 Dosing Regimen
Table 4.1: Treatment arms and corresponding dosing techniques

Once the xenograft cells were implanted into the mice, the tumors grew for two weeks until they
3
were approximately 100150 mm
in size. Mice with tumors that were either too large or too

small and were dismissed from the study. The mice were then shuffled into groups based on this
measurement to ensure that a range of tumor sizes were represented, while maintaining a
3
common average of about 150 mm
for each group. Once the mice were shuffled, eight treatment

arms were created to test the different drug therapies.

4.4 Dosing Schedule
Our dosing schedule consisted of three drugs, two monoclonal antibodies, “mAb1” and
17

“mAb2”, as well as a small molecule drug, “Drug S”. The monoclonal antibodies acted as our
controls in the study. mAb1 represented the negative control, meaning that it is ineffective at
reducing tumor size. mAb2 represented the positive control because it demonstrates the trend of
effective tumor reducing treatment. Drug S, the small molecule drug, is our experimental drug,
which we will compare to the negative and positive controls, as well as a control group
containing no active treatment.

As can be seen in Table 4.2, mAb2 or its vehicle was dosed once per day, every day except
Thursday. Drug S or its vehicle was dosed twice per day, every day except Thursday. On
Thursdays, when mAb2 and Drug S were not administered, mAb1 or its vehicle was dosed
instead. The dosing amount for each drug is based on weight and was calculated based on the
expected weight of a 20 gram mouse. The dosing volume for Drug S was approximately 200
microliters, whereas the dosing volume for mAb1 and mAb2 was approximately 90 microliters.
Table 4.2: Dosing Schedule

Dosing frequency (Table 4.2) is determined based on the pharmacokinetics property of the drug.
In general, small molecules have a much shorter halflife in animals or human beings, ranging
from a few minutes to a few hours. mAbs generally have a much longer halflife in vivo, ranging
from hours to days. Halflife refers to the time it takes for the concentration of a substance, such
as a drug, to be reduced by onehalf. This is the duration of the action of a drug. This explains
why Drug S, as a small molecule drug, is dosed twice per day. Monoclonal antibodies can vary

18

in halflives, explaining why mAb2 must be dosed every day, while mAb1 is dosed only once a
week. The longer the halflife of a drug is, the less frequently it must be dosed.

4.5 Data Collection
The first quantitative measurement used was body weight. These measurements began for each
treatment group on the first day of dosing, and continued to be recorded multiple times a week as
specified by the client.

Average body weight for the SCID mice we tested is expected to be between 18 and 20 grams.
Changes in this expected body weight can be a good indicator of drug toxicity. A significant
body weight drop of 15% or greater, as specified by the client, over the course of the study is
indicative of a toxic drug and treatment is stopped.

To quantify our data, we also measured tumor size over the course of the study. Tumor
measurements were taken twice per week, on Tuesday and Friday, using a digital caliper (Figure
24
4.3).
A caliper is a device used to measure the distance between two opposite sides of an object.

Digital calipers allow for the measurement to be recorded electronically when connected to a
computer. To measure the tumors, we first measured the length (L) of the tumor, then the width
(W). These values were sent to the
computer where they were used to
calculate the total tumor volume according
to the following formula:
(L*W 2)
2

(eq. 1)
Figure 4.3: Digital caliper for tumor volume measurements
Source: "Precision Digital Caliper"

Measurement by digital caliper is currently the accepted method in industry. In order for this
method to be viable, the same individual must consistently take each measurement to ensure
25
precision of data. This allows the data to be accurately analyzed for relative tumor growth.

19

Chapter 5: Results
5.1 Body Weight
As seen in Table 5.1 each group was within the expected range of average body weight at the
start of the study. All but Groups 2 and 3 ended the study still within the expected range. Groups
2 and 3 had the greatest decrease in body weight over the course of the study. Group 2 exhibited
a 11.8% decrease and Group 3 exhibited a 14.5% decrease, so mAb1 alone and the
mAb1/mAb2 combination are not considered to be toxic treatments.
Table 5.1: Average body weight (g) and percent body weight decrease

Figure 5.1: Average body weight measurements for all groups

Figure 5.1 shows fluctuations during the first few days of measurement. This is due to the time
of day during which the mice were weighed. These mice tend to weigh one gram heavier in the
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morning than in the evening. There is a general up and down trend common to all of our
experimental groups, suggesting that they may have been measured in the evening on Day 3
while they may have been measured in the morning on Day 4. This can sometimes occur when
there are other experiments in the lab that have higher priority at a certain time.

5.2 Tumor Size
3
Table 5.2: Average tumor volume (mm
) and percent tumor volume increase

Figure 5.2: Average tumor measurements for all groups
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Controls
Our negative control, Group 2, demonstrates the trend (Figure 5.2) of a nontumor reducing
treatment with an exponentially increasing curve and 547% increase in tumor size (Table 5.2).
Group 1, the vehicle only group, follows the trend of the negative control, which is consistent
with what we expected for untreated tumors. Group 6 is the positive control and demonstrates the
trend (Figure 5.2) of an effective tumor reducing treatment due to the decreased rate of tumor
growth (273% increase, Table 5.2) relative to the negative control. Group 3 contains both the
positive and negative control, and exhibits a similar trend of tumor expansion to that of the
positive control alone (Figure 5.2).

Receptivity of Drug S
All groups containing Drug S exhibit trends similar to those of the negative control and vehicle
only groups, suggesting Drug S is not an effective treatment for MDAMB231 tumors (Figure
5.2). All groups containing Drug S had a greater than 500% increase of tumor size. When Drug S
was put in combination with the negative control in Group 6, we observed the greatest percent
increase in tumor growth (612%, Table 5.2) among all the treatment groups. Therefore there was
no tumor reducing benefit in this combination of mAb1 and Drug S.

When Drug S was combined with the mAb2 positive control in Group 8, tumor growth followed
the negative control trend, rather than that of the positive control. Similarly, our drug cocktail
containing mAb1, mAb2, and Drug S (Group 4) follows the trend of the negative control tumor
growth trend, suggesting Drug S reduced mAb2’s effectiveness to that of a nontumor reducing
treatment (Figure 5.2).
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Chapter 6: Discussion
6.1 Toxicity
Although none of our treatment arms reached the 15% body weight decrease (Table 5.1) that
indicates drug toxicity, Group 3 was bordering this limit, and should therefore not be discounted.
The solvent used to carry the mAb drug compounds, dimethyl sulfoxide (DMSO), may have
caused this drop in body weight. DMSO is a solvent commonly used to solubilize compounds to
facilitate drug delivery. Although used in numerous studies, injected DMSO can induce
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apoptosis of cells by interfering with their plasma membrane compositions.

All of the treatment groups containing mAb1 demonstrated a decrease in body weight, while all
others (excluding Group 1) exhibited an overall increase in body weight. This suggests that the
concentration of DMSO used in mAb1 formulations may have contributed to the greater body
weight disruptions in Groups 2 and 3. While it is comparably effective to the positive control, the
mAb1 and mAb2 combination (Group 3) had potentially toxic effects. Therefore, the positive
control alone should be considered for use above the combination of the two controls. Future
studies should be conducted to reevaluate the composition of these treatment groups’
compounds.

6.2 Effects of Drug S on Controls
When Drug S was given in combination with the mAb1 or mAb2 control, the treatment was
less effective than the vehicle only group. Group 8, which contains mAb1 and Drug S, was least
effective at reducing tumor growth (Table 5.2). These nontumor reducing effects may be due to
negative drug interactions. We can be certain it is Drug S which causes these negative
interactions because of the different treatment arms we analyzed. We can see that when mAb1
and 2 are combined, they do not seem to have any negative drug interactions, so the treatment
continues to be effective (Figure 6.1).
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Figure 6.1: Average tumor measurements for controls and cocktail

Small molecule drugs work by interfering with cellular pathways within the cell; mAb’s, on the
other hand, targets receptors on the outside of the cell, causing a cascade which disrupts the
cell’s natural pathways (See Chapter 3.2). When mAb2, our positive control, bound to the
outside of the cancer cell, it had either initiated or disabled a cellular pathway leading to
apoptosis. This mechanism slowed tumor growth in Group 6.

In Group 8, when mAb2 was paired with our small molecule, Drug S, it is likely that the
mechanism used by Drug S interfered with the signaling pathway usually affected by mAb2.
This interference therefore prevented mAb2’s usual tumor reducing effects.

6.3 Metastasis of MDAMB231 Tumors
By the end of the study, many of the MDAMB231 tumors had metastasized to the lungs and
heart. From our literature research we have found that the MDAMB231 is an aggressive cell
line commonly used to model metastasis, or the spread of cancer to other areas of the body, in
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xenograft cancer studies.
This cell line has high levels of autophagy due to increased

permeability of mitochondrial pores. This autophagy in the MDAMB231 cell line allows for
increased rates recycling of old proteins and cell debris to fuel the anabolic needs of the cancer
24

28
cells.
This results in faster and more efficient proliferation and spread of the cancer cells.
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Chapter 7: Summary and Conclusions

7.1 Summary
Our study demonstrated the effects of small molecule and mAb drugs on MBAMB231 tumors
in CB17 SCID mice. Treatment groups containing small molecule Drug S did not prove to be
effective tumor reducing drug candidates. The positive control, mAb2, alone was the most
effective treatment as it reduced the rate of MDAMB231 tumor growth by 72% (Table 5.2)
when compared to the vehicle only group (Group 1). Even when in combination with mAb2,
Drug S facilitated the greatest percent increase in tumor size among the treatment arms;
therefore, Drug S is an inefficacious breast cancer treatment.

7.2 Future work
When we report our data to the client pharmaceutical company, we will suggest they attempt to
alter their formulation of Drug S and conduct more 
in vitro
testing prior to attempting more
preclinical trials. If Drug S is no longer a viable option, we suggest searching for a small
molecule drug that will work in conjunction with our positive control to amplify, rather than
contradict, the signaling pathways needed to kill the cancer cells.

An additional consideration that the client may address in future research is using a different cell
line. By the end of our study, many mice had tumors that had metastasized, affecting their lungs
and other organs, making the cancer too difficult to treat. Perhaps if the client were to test Drug S
on a less aggressive cell line, they may be able to better identify how it affects intracellular
cancer cell pathways. Then Drug S may be strengthened so it can be used to treat more
aggressive forms of cancer.

7.3 Conclusions
As we discussed before, this process of drug development takes many years and thousands of
drug candidates to sift through. While Drug S did not prove to be an effective form of treatment
due to the results of this study, our project was ultimately successful. From here, we can inform
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the client of our findings so that they may reformulate Drug S and get us one step closer to
finding a drug that will be able to combat this complex disease.
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